New combo therapy shows promise for tough lymphoma cases
NCT ID NCT03210662
First seen Jan 13, 2026 · Last updated Jun 12, 2026 · Updated 26 times
Summary
This study tested whether adding radiation to an immunotherapy drug (pembrolizumab) could help people with non-Hodgkin lymphoma that returned or didn't respond to prior treatments. Seventeen adults with aggressive types of lymphoma received both treatments. The goal was to see if the combination could shrink tumors better than the drug alone. While not a cure, this approach aims to control the disease and improve outcomes for patients with limited options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT T-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.